Promedicus USA's initiative to distribute My Safe Pass - Rapid symptom screening, olfactory tests

Early detection of today's leading major medical diseases and disorders can make all the difference in protecting our health. Early detection allows for effective treatment and positive outcomes for patients with health disorders that mostly go undetected and unnoticed. Decades of clinical research has proven these symptoms occur, but until now there was no quick, affordable, way for medical providers to detect them.

Scent accuracy changes are the first and many times the only symptom of many diseases and disorders that go undetected. For example slight losses of scent due to COVID 19, sino nasal disease as well as mild to moderate concussion. In fact hyposmia (decrease sense of smell) is the earliest symptom of many neurological diseases such as Alzheimer's, Parkinson's, Huntington's disease and many others.

Promedicus USA, under the leadership of Sean Heileman and his business partner Jon K. Roberts, recognized the need for a solution to diagnose these conditions earlier. His vision led to a global distribution partnership with My Safe Pass, an innovative olfactory test designed to identify hidden and unnoticed scent accuracy and scent sensitivity levels and changes of our ability to smell.

While humans can detect over one trillion odors, smell loss often goes unnoticed daily. My Safe Pass employs extensive research into “olfaction” to identify smell disorders linked to many illnesses.

Developed by scientists and doctors, the MSP (My Safe Pass) olfactory test has now received its class 2 medical device rating and is designed to detect mild to moderate scent losses.

Decades of NIH published evidence as well as hundreds of clinical studies published in most major medical journals, prove that detecting these scent losses are needed to detect this early-stage symptom of associated health disorders including, mild to moderate concussions, Alzheimer’s, Parkinson’s, and COVID-19 and many more. Early detection and preventative care assessments can save lives and allow for earliest corrective treatment.

Using the most effective clinically studied scents along with a scent encapsulation process proven to detect these mild scent changes, The My Safe Pass test consists of a 5 scent rub and smell odorant card along with an objective AI web application test – Patients sniff each scent area and identify the scent from multiple choices along with the level of scent intensity. MSP is fast, low cost and non-invasive and gives medical providers results in seconds. Results indicating a smell disorder alert providers to further investigate. My Safe Pass provides HIPAA protection based testing along with patient tracking as well as quicker insurance billing. MSP’s ease of use makes it capable for general public use as well.

Originally designed to detect asymptomatic first day viral symptoms, My Safe Pass proved equally applicable for concussion, TBI, neurological diseases like Alzheimer’s and Parkinson’s screening, and many other health issues that are shown to cause olfactory disorders. The advent of COVID-19, with smell loss as a primary symptom, underscored the test’s versatility. My Safe Pass is now recommended by healthcare networks worldwide for routine patient assessments. Promedicus USA helps integrate My Safe Pass into medical workflows, including electronic health record systems.

Promedicus USA's expansive supply chain and healthcare provider network enable broad delivery of My Safe Pass testing kits to facilities and individuals across the U.S. and overseas. Sean Heileman views the distribution partnership as an opportunity to advance preventative care. “We want to empower people to take charge of their health through early screening,” he said. “Widespread access to My Safe Pass can help safeguard brain and bodily health.”

Promedicus USA and My Safe Pass have navigated a complex labyrinth of challenges to bring this innovative solution to the healthcare industry. Chief among these was raising awareness about the significance of olfactory testing. They tackled this through targeted educational programs and outreach to healthcare professionals, making a compelling case for its utility in medical diagnosis.

Overcoming a significant challenge involved establishing the scientific credibility of My Safe Pass. The test successfully navigated through rigorous FDA validation processes, ensuring its reliability and accuracy. To address regulatory hurdles and comply with strict data security standards, the implementation of stringent measures was crucial. My Safe Pass not only met these requirements but also emerged as a valuable and necessary symptom screening tool, welcomed for its efficacy and precision.

While increasing access remains key, research continues uncovering new olfactory testing applications. “The future possibilities are exciting,” said Heileman. “As our knowledge of olfactory biomarkers expands, tools like My Safe Pass can help unlock preventative solutions for various health conditions."

Promedicus USA’s partnership with My Safe Pass illustrates the power of health tech innovation combined with effective distribution practices. Heileman summarizes the initiative simply: “We aim to maximize access and scale while never compromising on scientific rigor, quality, and safety - that’s how we can truly fulfill our mission of safeguarding health.” As olfactory testing gains traction, Promedicus USA aims to be the driving force enabling its widespread adoption and benefits realization.